Dyadic International Inc (DYAI) Stock AnalysisDYAIStock AnalysisDyadic International Inc

Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Dyadic International Inc is not a good buy right now due to its significant losses and declining stock performance. The current price is 0.6141, and the stock has seen a 41.51% drop over the last 20 days. Additionally, the RSI is extremely low at 12.542, indicating oversold conditions but also reflecting weak momentum. The main risk is the company's net income, which has been consistently negative, with a reported loss of -2,123,884 USD in Q2 2026, raising concerns about its financial stability.